Objective: Neuropeptides NPFF and NPSF are involved in pain control, acting through the G-protein coupled receptors (GPR)74 (high affinity for NPFF) and GPR147 (equal affinity for NPFF and NPSF). GPR74 also inhibits catecholamine-induced adipocyte lipolysis and regulates fat mass in humans. The aim of this study was to compare the effects of NPFF and NPSF on noradrenalineinduced lipolysis and to determine the expression of their receptors in human fat cells. Design: Adipose tissue was obtained during surgery. Adipocytes were prepared and kept in primary culture. Lipolysis, protein expression and gene expression were determined. Results: NPFF counteracted noradrenaline-induced lipolysis, which was more marked after 48 h than after 4 h exposure and was solely attributed to inhibition of b-adrenoceptor signalling. NPSF counteracted noradrenaline-induced lipolysis maximally after 4 h of exposure, which was attributed to a combination of inhibition of b-adrenoceptor signalling and decreased activation of the protein kinase-A hormone sensitive lipase complex by cyclic AMP. Both neuropeptides were effective in nanomolar concentrations. NPFF and NPSF had no effects on the expression of genes involved in catecholamine signal transduction. Both GPR74 and GPR147 were expressed at the protein level in fat cells from various adipose regions. GPR74 mRNA levels were higher in adipose tissue from obese as compared with non-obese subjects. High gene expression of either receptor correlated with low noradrenaline-induced lipolysis (Po0.05). Conclusions: Pain controlling neuropeptides NPFF and NPSF may be important for the regulation of lipolysis in man probably acting through GPR74 and GPR147. At low concentrations they inhibit catecholamine-induced lipolysis through rapid and longterm post-transcriptional effects at several steps in adrenoceptor signalling in fat cells.
Introduction
Neuropeptide FF (NPFF) is a neuropeptide expressed in several areas of the central nervous system (including the hypothalamus, the medulla and the dorsal horn of the spinal cord). 1 Studies in rodents suggest that NPFF is involved in pain control. 1 However, NPFF may have multiple effects as other studies in rodents demonstrate cardiovascular effects 2 and influence on food intake. 3, 4 The fact that NPFF in humans is secreted in the circulation in a pulsatile fashion suggests that this peptide may have a hormonal function. 5 NPFF interacts with Gi/o-protein coupled receptors termed GPR74 and GPR147. [6] [7] [8] [9] These two receptors may have specific roles in NPFF-action because they are differentially coupled to G-proteins. 10 After binding of NPFF (and related neuropeptides) to GPR it can induce stimulatory or inhibitory effects on the cyclic AMP system depending on how GPR is linked to the different G-proteins (G i , G s and G o ). This coupling is influenced by receptor subtype (74 or 147) and cell type. The role of NPFF in humans has been completely unknown until recently, when evidence was presented for a possible role in regulation of lipolysis in vitro. 11 In human fat cells, NPFF inhibits catecholamine-induced lipolysis and knock down of GPR74 in these cells is accompanied by augmentation of catecholamine-induced lipolysis. 11 Furthermore, a polymorphism in GPR74 influences body weight and fat cell lipolysis in humans. 11 A common haplotype is associated with a 50% risk of reduction of obesity, increased lipolytic activity in vivo and increased catecholamineinduced adipocyte lipolysis in vitro. 11 These data suggest that NPFF has a hitherto unrecognized role in regulating lipolysis and body fat storage. It is possible that this action is human specific, as in contrast to the inhibiting action in human fat cells, NPFF stimulates catecholamine action in rodent adipocytes. 12 In this study, we have investigated the effect of NPFF and NPSF on human fat cell lipolysis. NPFF has higher affinity for binding to GPR74 than for GPR147, whereas NPSF has equal binding affinity for GPR74 and GPR147. 10, 13, 14 Our primary hypothesis was that these neuropeptides are regulators of human fat cell lipolysis, which is achieved by interacting with their target receptors. The second hypothesis was that the neuropeptide regulation of lipolysis is influenced by obesity. We investigated the effect of NPFF and NPSF on lipolysis in both obese and lean subjects. In addition, we compared adipocyte expression of GPR74 and 147 between obese and lean subjects. Our results suggest that, first, both GPR74 and 147 are present in human fat cells and may induce different effects on lipolysis after activation through their cognate controlling neuropeptide ligands and, second, that obesity influences neuropeptide action on lipolysis.
Materials and methods

Subjects and adipose tissue
The study comprised of two cohorts. Cohort 1 consisted of 18 healthy women and 5 healthy men undergoing bariatric surgery for obesity or abdominal liposuction for cosmetic reasons. There was no selection on the basis of age, sex or body weight. Body mass index varied between 21 and 43 kg m À2 . Age varied between 19 and 60 years. None was on continuous medication. In the case of liposuction we obtained subcutaneous adipose tissue as a waste product from the cosmetic surgery. From bariatric surgery we obtained subcutaneous adipose tissue as a biopsy from the surgical incision (always) and as a biopsy from omental (visceral) adipose tissue (when possible). The tissue samples were used to investigate the effects of NPFF or NPSF on lipolysis in obese and nonobese subjects and to compare GPR74 and GPR147 expression between omental and subcutaneous adipocytes. Cohort 2 consisted of 58 medicine free and healthy women (age 22-57 years). In all, 11 were lean (BMI 20-24 kg m À2 ) and 47 were obese (BMI 31-53 kg m À2 ). They came to the laboratory in the morning after an overnight fast. A subcutaneous fat biopsy was obtained from the abdominal area under local anaesthesia. One piece (about 500 mg) was kept at À70 1C for subsequent mRNA studies. The remaining part was processed immediately for the isolation of mature adipocytes and subsequent lipolysis experiments. In cohort 2 the expression of GPR74 and 147 was set in relation to adipocyte lipolysis.
The study was approved by the Ethical Committee of the Karolinska Insitutet at Karolinska University Hospital. It was explained in detail to each subject and his or hers informed consent was obtained.
Isolation and differentiation of preadipocytes
The isolation of mature fat cells and differentiation of preadipocytes from the stroma-vascular fraction of adipose tissue was carried out as described. 15 The fat tissue was cut into small pieces and washed several times in phosphatebuffered saline immediately after arrival to the laboratory and incubated in 0. . Cells were maintained in this differentiation medium at 37 1C, in 5% CO 2 for about 6 days after which rosiglitazone was removed. They were refed every 2-3 days, until the day of the lipolysis experiment, which was at day 14. Before the lipolysis experiment, adipocytes were treated with NPFF or NPSF for 4 or 48 h. The fully differentiated adipocytes were exposed to the neuropeptides for a short (4 h) and long (48 h) time in order to sort out acute effects related to rapid lipolysis signalling or to sort out slower changes in the generation or degradation of proteins involved in lipolysis regulation. We only used the preparations when adipocyte differentiation was 480% of total cells. Treatment with neuropeptides did not influence adipocyte differentiation as evidenced from glycerol-3-phosphate dehydrogenase measurements (values not shown).
Lipolysis
In vitro differentiated adipocytes were subjected to lipolysis experiments exactly as described previously. 15 In brief, cells were washed with DMEM/NUT.MIX.F.12 medium and then The freshly isolated mature fat cells from the subjects in cohort 2 were studied as described in detail. 9 In brief, isolated fat cells were incubated for 2 h at 37 1C in an albumin containing buffer (pH 7.4) without (basal) or with different concentrations of noradrenaline (10
). Reported values are basal release and release at the maximum effective noradrenaline concentration.
After incubation of either freshly isolated mature cells (cohort 2) or differentiated adipocytes (cohort 1) the medium was removed and kept at À20 1C for subsequent measurement of glycerol concentration (an index of lipolysis) using an ultrasensitive method. 16 Methodological experiments revealed that during the incubation period glycerol release was linear with time. Release of glycerol was expressed as the concentration in the medium per protein concentration in the differentiated adipocyte experiments and as total glycerol released into the incubation medium per number of cells in the mature adipocyte experiments.
Western blot experiment
Proteins were extracted from differentiated adipocytes in wells not used for lipolysis experiments (cohort 1), using a protein lysis buffer that contained 1% Triton X-100, 50 mmol l À1 TrisHCl (pH 7.6), 150 mmol l À1 NaCl and PMSF (1 mmol l
À1
), supplemented with protease inhibitors (Complete; Boehringer Mannheim, Indianapolis, IN, USA). Protein concentration was determined spectrophotometrically using a kit from BioRad kit. Western blot analysis was carried out as described previously. 15 A total of 50 mg of total protein was loaded on 12% polyacrylamide gels and separated by standard SDS-PAGE. Proteins were transferred onto a PVDF transfer membrane (Hybond-P, GE-Healthcare, Amersham Place, Little Challfont, UK). Blots were blocked for 1 h at room temperature in Tris-buffered saline with 0.1% Tween-20 and 5% nonfat dried milk. This was followed by an overnight incubation at 4 1C in the presence of primary antibodies directed against b-actin, GPR74 and GPR147. The antibody against b-actin was from Sigma and those against GPR74 and GPR147 from Bachem (Weil am Rein, Germany). Antigen-antibody complexes were detected by chemiluminescense using a kit from Pierce (Supersignal; Rockford, Rockford, IL, USA), and blots were exposed to high-performance chemiluminescence film (Amersham Place, Little Challfont, UK).
mRNA analysis
Total RNA was extracted from the frozen tissue pieces (cohort 2) or from the adipocytes (cohort 1) and the mRNA levels were determined as described 17 using the RNeasy mini kit (Qiagen GmbH, Hilden, Germany) and the RNA concentration and purity was assessed spectrometrically and by AGILENT Bioanalyzer (Santa Clara, CA, USA). Between 0.125 and 0.5 mg of total RNA from the different experiments was reversetranscribed to cDNA. Quantitative real-time-qPCR was carried out in an iCycler IQTM (BioRad Laboratories, Hercules, CA, USA). GPR74 and GPR47 mRNA, as well as all other mRNAs mentioned in the Results section were quantified using a TaqMan kit (Applied Biosystem, Foster City, CA, USA). For internal control an 18S TaqMan kit was used. Expression of GPR74 mRNA was normalized to the 18S internal control using the formula: 2
, where calibrator is a random sample.
Drugs and chemicals
Bovine serum albumin fraction V (Lot No. A-9418), noradrenaline, dcAMP, glycerolkinase from Escherichia coli (G-4509), neuropeptides and yohimbine were obtained from Sigma Chemical. ATP monitoring reagent containing firefly luciferase came from BioThema (Stockholm, Sweden). All chemicals used were of the highest grade of purity that was commercially available.
Statistical analysis
Values are given as mean±standard error (s.e.). Repeated measured analysis of variance (ANOVA) or Student's t-test were used for statistical comparisons. Pp0.05 (two-sided) was regarded as statistically significant. mRNA ratios for GPR74 and GPR147 were not normally distributed and were compared between groups using Mann-Whitney U-test. Standard software packages were used for calculations.
Results
With regard to lipolysis, it was not possible to obtain reproducible results with either of the neuropeptides using freshly isolated omental or subcutaneous mature fat cells in acute experiments (2 h of incubation). As these cells display a short half-life in suspension they are not suitable for long-term studies and therefore all subsequent neuropeptide experiments in cohort 1 were carried out on adipocytes differentiated in vitro from adipocyte precursor cells which are more stabile in culture. We focused on subcutaneous adipocytes because of difficulties in obtaining sufficient amounts of omental adipose tissue. Figure 1 shows the effects of NPFF and NPSF on adipocyte lipolysis. Both agents were added at a maximum effective concentration of 1 mmol l
À1
. 18 Differentiated adipocytes were first exposed to no peptide (control) or peptide during 4 or 48 h and thereafter subjected to lipolysis experiments. Neither of the neuropeptides influenced basal (spontaneous) (Figure 1a) . However, it decreased noradrenaline-induced lipolysis significantly when the antilipolytic (a2-adrenoceptor-mediated) effect of the hormone was blocked with yohimbine (unmasking the b-adrenoceptor-mediated lipolytic action of noradrenaline). This counteracting effect of NPFF was time dependant (Po0.01 by ANOVA-repeated measures). Treatment with NPFF for 48 h reduced the lipolytic effect of noradrenaline þ yohimbine by 35% (Po0.001). A clearly different pattern was observed with NPSF ( Figure 1b) . For noradrenaline or noradrenaline plus yohimbine it reduced lipolysis by about 50% (Po0.01 and Po0.001, respectively) already after 4 h but in longer treatments (48 h) this effect disappeared. In contrast, dcAMP-induced lipolysis was significantly counteracted by NPSF and the maximum effect was observed after 4 h and remained after 48 h exposure (about 60% reduction).
We had information on body mass index so the samples could be subdivided into donors being non-obese (n ¼ 6) and obese (n ¼ 6), We examined the effect of body weight status on the most evident neuropeptide effects described above at 48 h of neuropeptide exposure namely noradrenaline þ yohimbine for NPFF and dibutyryl cyclic AMP for NPSF. In Figure 2 it is observed that both neuropeptides significantly counteracted lipolysis in differentiated adipocytes from both obese and nonobese donors.
The concentration dependency of the effects of NPFF and NPSF on lipolysis was investigated in Figure 3 . The experiments were carried out at the neuropeptide's most effective exposure time (48 h for NPFF and 4 h for NPSF). NPFF caused a concentration-dependent effect on noradrenaline þ yohimbine-induced lipolysis (Po0.001) by ANOVA (Figure 3a) . A small but significant effect was observed at the lowest concentration of NPFF (10 À10 mol l À1 , Po0.05 by t-test). NPSF in the same concentration range as NPFF also caused a concentration-dependent inhibition on noradrenaline þ yohimbine-induced lipolysis (Figure 3b , Po0.001 by ANOVA). A marked effect was observed already at the lowest concentration which was 10 À10 mol l À1 (Po0.01 by t-test).
The effect of the neuropeptides on mRNA expression of key genes involved in adipocyte lipolysis was also examined in cohort 1. Differentiated adipoyctes were incubated with 1 mmol l À1 of either NPFF (10 different experiments) or NPFF (7 different experiments). No significant difference was observed between control and neuropeptide-treated cells on Figure 2 Effect of body weight status on neuropeptide-induced lipolysis. Effect of (a) NPFF-48 h on noradrenaline þ yohimbine-induced lipolysis and effect of (b) NPSF-48 h on dibutyryl cyclic AMP-induced lipolysis described in Figure 1 were re-examined dividing the samples into 6 obese and 6 non-obese ones. *Po0.05, **Po0.01, ***Po0.001.
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mRNA gene expression for the following genes involved in lipolysis regulation: beta 1 -adrenoceptor, beta 2 -adrenoceptor, G ai -2 protein, G (a)s protein, beta-arrestin, phosphodiesterase3a, perilipin, hormone-sensitive lipase and adipose triglyceride lipase (P-values ranging from 0.078 to 0.84 on 10 log transformed specific genes/18S mRNA ratios). NPFF decreased the relative expression of G ai -1 slightly from 1.9 ± 0.3 to 1.5 ± 0.2 (P ¼ 0.050). However, this was considered as a random finding bearing in mind that 10 different genes were tested. A Bonnferoni correction gave a P-value of 0.45. Protein expression of GPR74 and GPR147 was examined by western blot (Figure 4 ) in cohort 1. Both receptors were clearly expressed in freshly isolated mature fat cells (Figure 4b ) as well as in vitro differentiated adipocytes from the omental and subcutaneous region (Figure 4a ). For the differentiated adipocytes, protein expression of GPR74 and GPR147 was compared between the adipose tissue regions. Similar levels were observed in both subcutaneous and omental fat cells (Figure 4a) .
In a clinical examination, the mRNA ratio to 18S rRNA for GPR74 and GPR147 was measured in RNA extracts from subcutaneous adipose tissue from subjects in cohort 2. GPR74, but not GPR147 mRNA was significantly lower in adipose tissue from obese as compared with non-obese Values (mean ± s.e.) were expressed as percentage over basal (no drug added) glycerol release. Ten unique experiments on samples from cohort 1 were carried out and compared by ANOVA.
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Freshly isolated mature adipocytes sc om sc om sc om sc om sc om sc om Neuropeptides and lipolysis V van Harmelen et al subjects (Figures 5a and b) . The values for the mRNAs were grouped into tertiles and the highest and lowest tertiles were compared for adipocyte lipolysis (Figures 5c and d) . No effect on basal lipolysis was observed. However, for both receptors a high expression was associated with a much lower rate of noradrenaline-induced lipolysis in comparison with low gene expression (Po0.05). Similar data with noradrenalineinduced lipolysis and mRNA were obtained when all values (thus also including the middle tertile) were used in linear regression (on 10 log-tranformed data to improve distribution). For GPR74 we obtained r ¼ 0.27 and Po0.05. For GPR147 we obtained r ¼ 0.53 and Po0.001.
Discussion
The recent discovery of a genetic link between GPR74, lipolysis and body fat in humans as well as the demonstration that a natural ligand for GPR74, NPFF, inhibits catecholamine-stimulated human adipocyte lipolysis 11 motivated us to make a more detailed analysis of this new regulatory system for adipocyte lipolysis in man. Neuropeptide FF and NPSF belong to a family of FMRF amide-like neurotransmitters acting as modulators of pain and endogenous opiod functions. 1 Two Gi/o protein coupled receptors have been designated as the major receptors for NPFF. 19 These data clearly demonstrate that both these receptors, GPR74 and GPR147, are present as proteins in human fat cells irrespective of origin (subcutaneous/ omental) or mode of preparation (natural freshly isolated mature fat cells or in vitro differentiated fat cells from progenitor cells).
Little is known about the mode of action and signal transduction of the two investigated receptors. Detailed examinations of signal transduction can only be carried out in cell systems with stable manipulation of the expression of either or both of the receptors. [5] [6] [7] [8] [9] 13, 14 Unfortunately at present it is not possible to carry out such studies in human adipocytes kept in primary culture. We therefore used an indirect approach by comparing the effect of NPFF with that of NPSF and by using selective lipolysis agents acting on defined steps in signal transduction. NPSF has almost equal affinity for GPR74 and GPR147, whereas NPFF has at least 10 times higher affinity for the former receptor. 10, 13, 14 Our results suggest that the two receptors mediate different effects on lipolysis. NPFF has no effect on catecholamineinduced lipolysis using the natural ligand noradrenaline alone. This hormone stimulates all adrenergic receptors coupled to human fat cell lipolysis, which are the antilipolytic a 2 -adrenoceptor and the lipolytic b 1,2,3 receptors. 17, 20 However, when the b-receptor response was fully unmasked by blocking the a 2 -(and a 1 -)-receptors with yohimbine, we demonstrated that NPFF can inhibit noradrenaline-induced lipolysis in a manner which is time and concentration GPR147 mRNA expression were determined in adipose tissue of obese (n ¼ 47) and non-obese (n ¼ 11) subjects. Relationship between adipose mRNA expression for (c) GPR74 and (d) GPR147, on the one hand, and adipocyte lipolysis, on the other hand was compared. For this purpose all subjects were put together. mRNA expression was divided into tertiles. Subjects with mRNA expression belonging to the middle tertile were excluded from analysis. Highest versus lowest tertile were compared by Student's t-test. NA ¼ noradrenaline.
Neuropeptides and lipolysis V van Harmelen et al dependent. A marked effect was not obtained until the fat cells had been treated for 48 h. This indicates that NPFF in some way interferes with the turnover of proteins involved in lipolysis regulation because such effects usually take some days to establish. However, there was no effect of NPFF (or NPSF) on mRNA expression for a number of key genes involved in lipolysis regulation including the genes for the enzymes involved in the final rate-limiting steps (that is, hormone-sensitive lipase and adipose triglyceride lipase). However, this does not exclude post-transcriptional effects of the neuropeptides. Unfortunately, the amount of adipocytes available was too small for an extensive protein analysis. When the catecholamine signal transduction was activated at the protein kinase A-hormone-sensitive lipase level with dcAMP, no effect of NPFF was observed. Taken together these data suggest that NPFF counteracts catecholamine-induced lipolysis by interacting with early steps in b-adrenoceptor signalling (before protein kinase A). This could be at the level of receptor, G i proteins, G s proteins or adenylate cyclase. Neuropeptide SF had an earlier onset of inhibition of lipolysis than NPFF. A maximum effect of NPSF occurred already after 4 h. Furthermore, NPSF counteracted lipolysis induced by noradrenaline alone, by noradreanline plus yohimbine and by dcAMP. Its effects seem to be at multiple levels of catecholamine activation, which include initial steps in b-adrenoceptor signalling and late steps located at inhibition of the protein kinase A-hormone-sensitive lipase complex. The early onset effect of NPSF implies that this neuropeptide interacts with several steps in catecholamineactivated-lipolysis signalling such as receptor binding/ coupling to G-protein and phosphorylation of kinases and lipases. An effect related to protein turnover is less likely. As with NPFF the antilipolytic effect of NPSF was concentration dependent.
When data with the two neuropeptides are taken together it appears that a more selective activation of GPR74 (with NPFF) slowly counteracts the initial b-adrenoceptormediated signalling steps to human fat cell lipolysis, whereas nonselective activation of GPR74 and GPR147 (with NPSF) has a more profound and rapid antilipolytic effect involving multiple initial and late steps in catecholamine signalling to lipolysis. If these differences between NPFF and NPSF are because of different signal transduction properties of GPR74 and 147 or to additive effects of the two receptors cannot be sorted out at present. Highly selective agonists or antagonists with high affinity for each NPFF receptor are not yet available as discussed. 19 Selective receptor knock down with siRNA is also not of great value because it causes marked lipolytic effect of its own in human fat cells, at least for GPR74.
11
The present findings are in marked contrast to the results obtained with a mouse fat cell line. 12 In 3T3-L1 fat cells NPFF and NPSF augment b-adrenoceptor signalling, which occurs at the level of gene expression. Thus, the pain controlling neuropeptides are added to a long list of endogenous lipolysis regulators, which are subject to marked species differences in their ability to stimulate or inhibit lipolysis.
This list also includes catecholamines, insulin, atrial natriuretic peptide and tumour necrosis factor alpha. [20] [21] [22] [23] [24] [25] [26] [27] [28] Is the presently examined neuropeptide family of physiological importance for lipolysis regulation in man? No definitive answer can be given for the moment but there is evidence to suggest a functional role. Genetic variance in GPR74 is closely linked to lipolysis and obesity status. 9 NPFF is present in the circulation of humans where it is subject to regulation. A pulsatile secretion is demonstrated 5 and the concentration increases markedly following electron convulsive therapy. 29 In these clinical studies the circulating concentrations reach about 10 pmol l
À1
. In our studies significant in vitro effects of NPFF and NPSF were obtained with 100 pmol l
. However, the concentration of the neuropeptides in adipose tissue may be much higher than in the circulation because they are classified as neurotransmitters. 29 NPFF is released in high concentrations from rat spinal cord slices. 30 It is possible (although not demonstrated) that NPFF, NPSF and other members of the neurotransmitter family acting on GPR74 and GPR147 are released from nerve ending in adipose tissue causing much higher concentrations at the adipocyte level than in the circulation. Unfortunately, there is no available assay to determine the circulating levels of the neuropeptides. A further evidence for a clinical role of the NPFF/NPSF system in lipolysis is the present finding that high adipose expression of either GPR74 or GPR147 mRNA is linked to low noradrenaline-induced lipolysis in vitro. In addition, the adipose expression of GPR74 was influenced in obesity and this condition is associated with alterations in lipolysis as discussed. 24 However, the neuropeptides seem effective on lipolysis independent of BMI as both NPFF and NPSF affected lipolysis in fat cells of obese as well as non-obese donors. In summary, NPFF and related neuropeptides may, in addition to their role in pain control, also be important regulators of human fat cell lipolysis by early and late inhibition of catecholamine-induced lipolysis at several steps in the signal transduction pathway. These neuropeptide effects are most likely mediated by GPR74 and GPR147.
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